GSK Raises Eyebrows in Checkpoint Inhibitor Megadeal with iTeos
Analysts are abuzz over GSK’s co-development deal with immuno-oncology specialist iTeos Therapeutics earlier this month,…
30/06/2021 - 5 minutes
Cancer: Keep up to Date with the Latest in Oncology
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
Show More
Editor's Picks for Cancer
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Immuno-Oncology: From Science Fiction to the Mainstream
- ADC Approval Buoys Spirits in Cancer Treatment Space
- Do Natural Killer Cells Hold the Key to Treating Blood Cancers?
- Meet 20 European Immuno-Oncology Companies that are Fighting Cancer
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest Cancer Articles
Scotland’s Top Ten Biotech Companies to Watch Out For
Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial…
30/06/2021 - 11 minutes
Immuno-Oncology: From Science Fiction to the Mainstream
In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry.…
26/05/2021 - 7 minutes
ADC Approval Buoys Spirits in Cancer Treatment Space
The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for…
11/05/2021 - 7 minutes
BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
29/04/2021 - 5 minutes
Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in…
20/04/2021 - 5 minutes
Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month…
15/04/2021 - 5 minutes
Base Editing: The Next Frontier in Genome Editing Technology
Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights…
05/04/2021 - 4 minutes
Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells
The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with…
31/03/2021 - 5 minutes
Developing a Vaccine that Protects Against Covid-19 Variants
Despite the promise of several approved Covid-19 vaccines and the widespread rollout of vaccination programs…
15/03/2021 - 8 minutes
Advice for my Younger Self: How to Be a VC in Life Sciences
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, looks back at where he was…
08/03/2021 - 5 minutes
The Promises of CRISPR Genome Editing in Biomedicine
Tony Ho, Head of Research and Development at CRISPR Therapeutics, offers his insights into the…
03/03/2021 - 5 minutes
